Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNFW NASDAQ:BRNS NYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNFW180 Life Sciences$0.32-15.8%$0.06$0.00▼$0.62N/AN/A501,334 shs843,775 shsBRNSBarinthus Biotherapeutics$1.14+3.4%$1.20$0.64▼$2.92$45.99M-0.73515,476 shs11,513 shsNVONovo Nordisk A/S$54.30-0.9%$64.03$45.05▼$139.74$242.44B0.6311.71 million shs14.04 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNFW180 Life Sciences-11.63%+256.81%+4,030.45%+5,035.15%+4,370.60%BRNSBarinthus Biotherapeutics-3.45%-5.82%-23.28%+38.58%-9.53%NVONovo Nordisk A/S+1.73%+9.95%-14.89%-19.72%-59.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ABRNSBarinthus Biotherapeutics2.6375 of 5 stars3.53.00.00.02.40.01.3NVONovo Nordisk A/S4.7358 of 5 stars4.15.02.50.03.70.03.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNFW180 Life Sciences 0.00N/AN/AN/ABRNSBarinthus Biotherapeutics 3.00Buy$3.00163.16% UpsideNVONovo Nordisk A/S 2.13Hold$81.0049.18% UpsideCurrent Analyst Ratings BreakdownLatest NVO, BRNS, ATNFW, and GWP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025NVONovo Nordisk A/STD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$105.00 ➝ $70.008/13/2025NVONovo Nordisk A/SBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral8/13/2025NVONovo Nordisk A/SBNP Paribas ExaneSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$54.008/5/2025NVONovo Nordisk A/SUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/31/2025NVONovo Nordisk A/SHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/31/2025NVONovo Nordisk A/SHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$57.007/30/2025NVONovo Nordisk A/SBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ABRNSBarinthus Biotherapeutics$14.97M3.07N/AN/A$2.54 per share0.45NVONovo Nordisk A/S$311.94B0.78$3.94 per share13.78$5.73 per share9.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ABRNSBarinthus Biotherapeutics-$61.07M-$1.73N/AN/AN/AN/A-54.70%-44.75%11/5/2025 (Estimated)NVONovo Nordisk A/S$14.64B$3.6414.9211.651.8435.60%78.64%24.51%11/5/2025 (Estimated)Latest NVO, BRNS, ATNFW, and GWP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025BRNSBarinthus Biotherapeutics-$0.29-$0.52-$0.23-$0.52N/AN/A8/6/2025Q2 2025 NVONovo Nordisk A/S$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNFW180 Life SciencesN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/ANVONovo Nordisk A/S$0.821.51%N/A22.53%N/ALatest NVO, BRNS, ATNFW, and GWP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/7/2025NVONovo Nordisk A/Ssemi-annual$0.41192.4%8/18/20258/18/20258/26/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNFW180 Life SciencesN/AN/AN/ABRNSBarinthus BiotherapeuticsN/A7.897.89NVONovo Nordisk A/S0.520.780.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNFW180 Life SciencesN/ABRNSBarinthus Biotherapeutics25.20%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipATNFW180 Life SciencesN/ABRNSBarinthus Biotherapeutics10.70%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNFW180 Life Sciences7N/AN/ANot OptionableBRNSBarinthus Biotherapeutics10740.34 million37.11 millionN/ANVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionableNVO, BRNS, ATNFW, and GWP HeadlinesRecent News About These CompaniesGoodRx teams up with Novo Nordisk to make weight loss drugs more affordable1 hour ago | consumeraffairs.comCNovo Nordisk’s New CEO Starts Hiring Freeze in Cost-Cutting Push1 hour ago | news.bloomberglaw.comNNovo Nordisk’s new CEO is said to start hiring freeze to cut costs1 hour ago | msn.comTop Growth Stocks To Add to Your Watchlist - August 19th3 hours ago | marketbeat.comDEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersAugust 20 at 12:07 PM | globenewswire.comNovo Nordisk halts hiring as new CEO's restructuring continuesAugust 20 at 10:37 AM | proactiveinvestors.comTD Cowen Has Lowered Expectations for Novo Nordisk A/S (NYSE:NVO) Stock PriceAugust 20 at 10:33 AM | marketbeat.comNovo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025August 20 at 9:31 AM | globenewswire.comNovo Nordisk: Cleared For A ClimbAugust 20 at 9:09 AM | seekingalpha.comVenture Visionary Partners LLC Has $4.27 Million Stock Holdings in Novo Nordisk A/S $NVOAugust 20 at 7:11 AM | marketbeat.com1 Reason to Buy NVOAugust 20 at 7:01 AM | fool.comAcademy Capital Management Purchases 213,453 Shares of Novo Nordisk A/S $NVOAugust 20 at 6:28 AM | marketbeat.comNovo Nordisk A/S (NVO) Reports 18% Sales Growth in H1 2025 Amid Market ChallengesAugust 20 at 5:51 AM | sohu.comSMatthew 25 Management Corp Takes Position in Novo Nordisk A/S $NVOAugust 20 at 5:46 AM | marketbeat.comBank OZK Has $360,000 Stock Holdings in Novo Nordisk A/S $NVOAugust 20 at 5:45 AM | marketbeat.comDrugmaker Novo Nordisk enacts worldwide hiring freeze for non-critical job rolesAugust 20 at 5:35 AM | reuters.comQuantbot Technologies LP Acquires New Position in Novo Nordisk A/S $NVOAugust 20 at 5:29 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Price Target Lowered to $70.00 at TD CowenAugust 20 at 2:05 AM | americanbankingnews.comNovo Nordisk halves Ozempic price to $499 for US patientsAugust 19 at 7:49 PM | njbiz.comNNovo Nordisk A/S (NVO) Reports 18% Sales Growth Amid Adjusted OutlookAugust 19 at 7:49 PM | sohu.comSNovo Nordisk A/S (NVO) Reports Impressive 18% Sales Growth Amid Strategic AdjustmentsAugust 19 at 7:49 PM | sohu.comSNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Why the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 2025Novo Nordisk Stock Sinks—But Is a Bottom Finally In?By Chris Markoch | August 5, 2025AbbVie Stock Eyes Breakout as Pipeline and Profits GrowBy Chris Markoch | July 31, 2025NVO, BRNS, ATNFW, and GWP Company Descriptions180 Life Sciences NASDAQ:ATNFW$0.32 -0.06 (-15.79%) As of 08/19/2025180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Barinthus Biotherapeutics NASDAQ:BRNS$1.14 +0.04 (+3.45%) Closing price 03:50 PM EasternExtended Trading$1.12 -0.01 (-1.32%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Novo Nordisk A/S NYSE:NVO$54.30 -0.48 (-0.88%) Closing price 03:59 PM EasternExtended Trading$54.23 -0.07 (-0.13%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Target: Missing the Mark in 2025—Downtrend May Continue Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNH Archer's Flight Milestones & Defense Wins Excite Wall Street Home Depot Holds Gains After Narrow Q2 Misses 2 Powerful Forces Now Back Intel's Turnaround The Case for Buying NVIDIA Stock Ahead of the Robotics Surge Medtronic: The Opportunity Gets Healthier for Income Investors Tesla's Breakout: Why This Rally Looks Far From Over Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access